PurpleAI Logo

Hyper Insight™ – CTA Aneurysm

Hyper Insight AI Detection Solutions

Comprehensive Stroke AI Platform

Hyper Insight™ – CTA Aneurysm

FDA in Progress
Cerebral Aneurysm Detection · CTA

AI software that detects and localizes unruptured intracranial aneurysms on brain CTA. It highlights abnormality, offers ROI visualization with size quantification, including lesions smaller than 3 mm.

AI Aneurysm Detection
ROI Visualization
Size & Shape ID

Radiological computer-aided detection software. Hyper Insight™ – CTA Aneurysm functions as a detection and visualization tool — supporting, not replacing, medical judgment. Final diagnosis and treatment decisions remain the responsibility of qualified medical professionals.

CTA Aneurysm 1

Medical Insight+™ Brain Aneurysm

RUOKFDA
AI Aneurysm Detection
ROI Visualization
Size & Shape ID

Not cleared or approved by the US Food and Drug Administration (FDA). This software is not for clinical use in the United States and is provided for research, evaluation, and educational purposes only.

Detection Sensitivity by Aneurysm Size

Sensitivity84.36%
Specificity92.56%

Per-lesion sensitivity across aneurysm size groups.

Size (mm)AI (A)Human (B)Diff (A−B)
3–487.30%66.00%+21.30%p
5–1093.07%84.00%+9.07%p
≥10100.00%99.00%+1.00%p
n = 396

Source: Clinical Study Report, Protocol No. SKAICA-01, Ver. 2.0, February 4, 2025, Ajou University Hospital, Seoul National University Hospital & CHA Bundang Medical Center, Korea.

Performance metrics reflect the latest metrics of internal validation.

Top 15 Industry Features Avail.

PACS integration / automated DICOM routingCloud or hybrid deploymentSecure team communication / collaboration

Industry-standard integration capabilities available with PurpleAI deployments.